title: Juvenile idiopathic arthritis.
abstract: Juvenile idiopathic arthrithis (JIA) is the most common rheumatic disease of childhood.JIA is a chronic disease that is associated with periods of disease flares and periods of disease inactivity.Early, aggressive treatment with nonsteroidal anti-inflammatory drugs, intra-articular corticosteroid injections, or methotrexate, has significantly improved the outcome of most children who have JIA. Biologics have been shown to be both safe and effective for the treatment of more aggressive forms of arthritis and for uveitis. Long-term safety data of biologics is still uncertain. In the near future, it is hoped that genetic testing will allow earlier diagnosis of JIA as well as help predict the disease course of children who have JIA. Genetic analysis also may allow physicians to target therapies more effectively. It is hoped that development of more specific therapies will decrease overall immunosuppression and other associated toxicities.
authors: The Steven and Alexandra Cohen Children's Medical Center of New York, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA.
authors: Maria
authors: M
authors: Espinosa
authors: Beth S
authors: BS
authors: Gottlieb
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D015535:Arthritis, Psoriatic / Q000175:diagnosis; D002648:Child; D006801:Humans; D007500:Iritis / Q000175:diagnosis / Q000209:etiology; D010348:Patient Care Team; D011379:Prognosis; D033581:Stem Cell Transplantation
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents